MUC16 and pancreatic intraductal papillary-mucinous neoplasm: The results of our study demonstrate that CA19-9 is the best serological biomarker to recognize invasive IPMN, and its combination with CA125 helps to overcome the unsatisfactory sensitivity of CA19-9 alone.